Articles

Preclinical

In-depth, citation-backed writing on preclinical. · 1 article in Preclinical

All Clinical Monographs Mechanisms of Action Pharmacovigilance Preclinical Regulatory Analysis
Preclinical

Does Catestatin Peptide Reduce Tau, Amyloid, and Neuroinflammation in Preclinical Alzheimer's Disease Models in 2026?

In preclinical models studied through 2026, catestatin (CST) — a 21-amino-acid peptide derived from chromogranin A — reduces tau hyperphosphorylation and aggregation, lowers amyloid plaque burden, suppresses glial neuroinflammation, and restores both cognitive and motor function. All evidence is from rodent models; no human clinical trials have been initiated as of 2026.

·11 min read